FDA has announced the availability of final guidance on assessing user fees under the Biosimilar User Fee Amendments of 2017. The guidance concerns FDA’s implementation of BsUFA II and certain changes in policies and procedures surrounding its appli- cation. [The BsUFA II negotiation process was reviewed in IPQ Dec. 5, 2016.]
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
